Informative censoring in a progression-free survival (PFS) analysis arises when patients are censored for initiation of an effective anticancer treatment before the protocol-defined progression, and ...

Targeting B-Cell Lymphoma 2: A Lethal Shortcut in Del(17p) Chronic Lymphocytic Leukemia ...

The impact of dietary patterns on inflammation and colon cancer risk: A retrospective study of 796 patients.

Febrile neutropenia remains an important complication of treatment with cytotoxic chemotherapy. It is often the first and sometimes the only sign or symptom of infection in this vulnerable patient ...

The guideline aims to optimize health and quality of life for the post-treatment prostate cancer survivor by comprehensively addressing components of follow-up care, including health promotion, ...

An open-label study to assess the safety and efficacy of naporafenib (ERAS-254) administered with trametinib in previously treated patients with locally advanced unresectable or metastatic solid tumor ...

The Impact of Varying Number of OSEM Iterations on Standardized Uptake Value and Image Quality of Discovery STE PET/CT Scanner This is an ASCO Meeting Abstract from the 2018 World Cancer Congress ...

Trends in PRO reporting in clinical trials leading to GU cancer drug approvals from 2007 to 2018. Treatment duration and response of advanced renal cell carcinoma (aRCC) patients (pts) who have ...

Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group Any hematologic toxicity grade 3 or 4 ...

Effectiveness of Physical Activity on Cardiorespiratory Fitness and Health-Related Quality of Life in Young and Middle-Aged Cancer Patients Shortly After Chemotherapy Surgery remains the standard ...

Lymphedema After Breast Cancer: Incidence, Risk Factors, and Effect on Upper Body Function In advanced NSCLC, cisplatin/pemetrexed provides similar efficacy with better tolerability and more ...

Validation of lymphocyte to monocyte ratio in resected small bowel adenocarcinoma as a predictor of survival. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This abstract does ...